Loading stock data…
DXCM
$61.35+1.80 (+3.02%)
Market ClosedLast close May 1
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DexCom, Inc. in the Healthcare sector is trading at $61.35. The stock is currently 32% below its 52-week high of $89.98, remaining 11.7% below its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why DXCM maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$61.35
Potential Downside
27%
Whystock Fair Value$44.81
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus24 analysts
Mean target$86.88+41.6%
Range$72.00 – $112.00
Fundamentals
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$24.47B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
30.34
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.56
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.81%
Volume
Today's trading volume
10.56M
Recent News
Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook
Dexcom has opted not to raise its FY26 revenue outlook due to the current geopolitical environment.
BTIG Remains Bullish on DexCom, Inc. (DXCM)
DexCom, Inc. (NASDAQ:DXCM) is one of the best medical device stocks to invest in right now. BTIG cut the price target on DexCom, Inc. (NASDAQ:DXCM) to $80 from $85 on April 13 and reaffirmed a Buy rating on the shares. The rating update came as part of a broader research note on Medical Technology, with […]
DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ...
DexCom Inc (DXCM) reports a robust 15% revenue increase, driven by international demand and strategic product launches, despite challenges in the US market.
DexCom (DXCM) Q1 2026 Earnings Transcript
Jacob Steven Leach, DexCom, Inc.'s President and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme M. Sylvain, our chief financial officer. Please note that there are also slides available related to our first quarter 2026 performance on the DexCom, Inc. Investor Relations website on the Events and Presentations page. All forward-looking statements included on this call are made as of the date hereof, based on information currently available to DexCom, Inc., are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements.
DexCom Q1 Earnings Call Highlights
DexCom (NASDAQ:DXCM) reported first-quarter 2026 revenue growth of 15% year over year, citing continued demand for continuous glucose monitoring (CGM) products, expanded access, and new product launches. Management also highlighted improving profitability and cash generation, along with ongoing effo